REGROTON
LOE ApproachingNDAORALTABLET
Approved
May 1964
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
REGROTON is an oral tablet small-molecule drug approved in 1964 as an NDA by Sanofi. Specific indications and mechanism of action are not publicly detailed in available data. The product is a legacy oral pharmaceutical with nearly 60 years of market presence.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30%), signaling potential team contraction and focus on retention/transition planning rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
REGROTON currently shows zero linked job openings, reflecting its LOE-approaching status and mature market position. Careers tied to this product are likely focused on managing decline, maximizing remaining patent life, or transitioning to next-generation assets.
Brand ManagerProduct Manager
Worked on REGROTON at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.